Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome
Thomas A Rasmussen, James McMahon, J Judy Chang, Jori Symons, Michael Roche, Ashanti Dantanarayana, Afam Okoye, Bonnie Hiener, Sarah Palmer, Wen Shi Lee, Stephen J Kent, Carrie Van der Weyden, H Miles Prince, Paul U Cameron, Sharon R Lewin
AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2017
OBJECTIVE: To study the effects of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy (ART) with Sezary syndrome, a rare malignancy of CD4 T cells. DESIGN: Case report. METHODS: Blood was collected 30 and 18 months prior to presentation with Sezary syndrome, at the time of presentation and during alemtuzumab. T-cell subsets in malignant (CD7-CD26-TCR-VBeta2+) and nonmalignant cells were quantified by flow cytometry. HIV-DNA in total CD4 T cells, in sorted malignant and nonmalignant CD4 T cells, was quantified by PCR and clonal expansion of HIV-DNA assessed by full-length next-generation sequencing. RESULTS: HIV-hepatitis B virus coinfection was diagnosed a..View full abstract
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
The study was funded by the National Health and Medical Research Council (NHMRC) of Australia program grant (PI Lewin). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the article.